GHRP-6 5mg/vial 1 Vial by Master Pharma

Usage

1. Confirm CJC-1295 DAC injection day for the week — schedule GHRP-6 on the same day and optionally a second day mid-week.
2. Reconstitute Master Pharma GHRP-6 5mg/vial by adding 2.5 mL bacteriostatic water along the vial wall to achieve a 2 mg/mL concentration.
3. Allow the vial to stand at room temperature for 5 minutes after adding solvent; do not agitate mechanically.
4. Draw the calculated volume into a U-100 insulin syringe (0.05 mL = 100 mcg; 0.10 mL = 200 mcg).
5. Administer subcutaneously into abdominal adipose tissue, rotating injection sites to avoid lipohypertrophy over a multi-week DAC protocol.
6. Store the reconstituted vial at 2–8 °C and use within 28 days; discard if solution appears cloudy or particulate.

Warnings

Frequently asked questions

How often should you inject GHRP-6 when using CJC-1295 DAC?

When CJC-1295 DAC is the base of the protocol, GHRP-6 is typically injected 1–2 times per week to coincide with each DAC administration, though some users add a third mid-week pulse injection. The DAC modification keeps the GHRH signal active for 6–8 days, so GHRP-6 frequency can be reduced compared to standard CJC-1295 (no DAC) protocols without losing anabolic continuity.

What does the Drug Affinity Complex modification do to CJC-1295 and why does it change GHRP-6 scheduling?

The DAC modification attaches a lysine-linked moiety that binds serum albumin, extending CJC-1295 half-life from roughly 30 minutes to approximately 6–8 days. This sustained GHRH-receptor activation means GHRP-6 pulses can be spaced across the week rather than dosed multiple times daily, substantially lowering injection frequency while preserving elevated IGF-1 output.

How much can CJC-1295 DAC plus GHRP-6 raise IGF-1 levels, and how is that measured?

Clinical pharmacokinetic data (Teichman et al., JCEM, 2006) show CJC-1295 DAC at 2 mg/week raises mean IGF-1 by 200–300 % above baseline, sustained for up to 9–11 days. Adding a GHS-R1a agonist like GHRP-6 amplifies peak GH pulse amplitude, which drives additional hepatic IGF-1 synthesis measurable via standard serum IGF-1 immunoassay.

How do you use GHRP-6 5mg/vial with an insulin syringe, and what volume should you draw for a 100 mcg dose?

Reconstitute the 5 mg vial with 2.5 mL bacteriostatic water to yield a 2 mg/mL (2000 mcg/mL) solution. A 100 mcg dose then equals 0.05 mL — the 5-unit mark on a U-100 insulin syringe. Inject subcutaneously, preferably into abdominal skin, and refrigerate the reconstituted vial at 2–8 °C for up to 28 days.

Is the 5mg/vial format sufficient for a full twice-weekly CJC-1295 DAC cycle, and how long does one vial last?

At 100 mcg per injection and twice-weekly dosing, one 5 mg vial provides 50 doses — approximately 25 weeks of GHRP-6 supply. Users running higher 200 mcg pulses twice weekly will use one vial over roughly 12–13 weeks. The 5 mg entry format is ideal for dialling in individual GH pulse response before committing to larger quantities. (2) angle_used

Manufacturer

The pharmaceutical team behind Master Pharma's peptide vial line combines analytical chemistry expertise with regulatory-grade process discipline — a staffing profile that shapes every decision from raw-material specification through final-lot release. For GHRP-6, that expertise is visible in two specific technical choices: the selection of personnel capable of running in-house HPLC potency assays rather than outsourcing to third-party contract laboratories, and the maintenance of LAL endotoxin testing competency as a standing quality-control function rather than an occasional audit activity. This internal skill set means batch data is generated by the same team that formulated the product, closing the information gap that can otherwise exist between manufacturing and quality departments in outsourced production models. Practitioner confidence in Master Pharma's lyophilised peptides ultimately rests on that human infrastructure — qualified analysts who understand the relationship between lyoprotectant selection, residual moisture targets, and the potency figures printed on the certificate of analysis.